Boundless Bio Merger Partner Serapha Reports Positive Interim SERP-01 Base Editing Data

summarizeSummary

Serapha Bio, the company Boundless Bio is merging with, reported first-in-human data showing its one-time base editing therapy SERP-01 restored protective AAT levels in all four PiZZ AATD patients, durable to 10 months, with no serious adverse events. For Boundless holders — who keep just 3.8% of the combined company — this is the first clinical validation of the asset the deal is built on.

check_boxKey Events · M&A and Partnerships · BOLD

• Positive First-in-Human SERP-01 Data

  A single administration of SERP-01 raised total serum AAT above the 11 µM protective threshold in all four PiZZ participants (n=1 at 35 mg; n=3 at 45 mg), with levels at or near the 20 µM lower limit of normal through up to 10 months in the 45 mg cohort.

• Precise Editing Confirmed in Biopsy

  A 10-week liver biopsy from the 35 mg participant showed 54% correction at the target site with no bystander editing at neighboring bases — described as the first reported hepatic gene correction with an LNP-delivered base editor in PiZZ AATD.

• Clean Early Safety Profile

  No serious adverse events and no treatment-related adverse events of grade 3 or higher were observed as of the October 15, 2026 data cutoff; Serapha notes longer follow-up and more participants are needed.

• Phase 2/3 Targeted for Late 2026/Early 2027

  The FDA has cleared an IND for a U.S. Phase 2/3 trial in PiZZ AATD and granted orphan drug and RMAT designations; Serapha intends to start the trial in late 2026 or early 2027.

auto_awesomeAnalysis · BOLD · Life Sciences

Boundless Bio's entire thesis now rests on its reverse merger with Serapha Bio, and this filing delivers the first human proof-of-concept for Serapha's only asset. In four PiZZ alpha-1 antitrypsin deficiency patients, a single dose of SERP-01 pushed circulating AAT above the protective threshold, shifted the protein to the functional M-AAT form, and held near-normal levels out to 10 months, with 54% target-site correction on liver biopsy and no grade 3 or higher treatment-related events. That is meaningful de-risking for a deal where existing Boundless holders keep only 3.8% of the combined company — the stock is effectively a levered bet on SERP-01, so better-than-expected clinical data directly raises the value of that stub. The caveats are real: four patients, an investigator-initiated trial not designed for approval, and a Beam Therapeutics trade-secret suit over SERP-01 still hanging over the program. Next hard checkpoint is the S-4 going effective and the shareholder vote, with Serapha targeting a U.S. Phase 2/3 start in late 2026 or early 2027.